Colorcon launches Opadry Enteric for use with hydro-alcoholic media

17 Jun 2019

A fully formulated one-step system providing simple preparation and ease-of-use for film coating.

Colorcon has announced another innovative addition to their portfolio of delayed-release coatings for pharmaceutical applications. This latest development incorporates hydroxypropyl methylcellulose phthalate (hypromellose phthalate or HPMC-P) as the functional polymer in an advanced one-step film coating system offering enteric performance for hydro-alcoholic applications.

Colorcon launches Opadry Enteric for use with hydro-alcoholic media

Opadry Enteric is a fully formulated one-step system providing simple preparation and ease-of-use for film coating; resulting in reduced inventory and QC testing compared to multi-component coating systems. This new system provides a further option to the company's existing Opadry delayed-release product line based on acrylic and PVAP polymers.

Dr Daniel To, Product Development Manager, explains: “As a fully formulated system Opadry Enteric, based on HPMC-P, brings not only convenience but also reduces potential errors of raw material handling and application during manufacturing. Our application data, generated during the product’s development, clearly demonstrates consistent and stable enteric performance for a number of APIs.”

Greater efficiency for solvent coating

Kelly Boyer, General Manager, Film Coatings at Colorcon notes: “Opadry Enteric is formulated for use with hydro-alcoholic media and can be color matched to meet the marketing and brand needs of pharmaceutical products. As a one-step hydro-alcoholic coating, preparation time is significantly reduced and, by using Colorcon’s expertise in color matching, batch-to-batch variability is eliminated.”

This new fully formulated delayed release coating, providing enteric protection represents Colorcon’s continued innovation and leadership in developing formulated film coating systems that bring enhanced functionality along with improved convenience for pharmaceutical formulators.

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Operations commence at Wasdell Group’s EU headquarters

Operations commence at Wasdell Group’s EU headquarters

8 Jul 2019

The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

Read more 
Porvair Sciences launches first Drosophila ChIP kits

Porvair Sciences launches first Drosophila ChIP kits

4 Jul 2019

Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.

Read more 
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

3 Jul 2019

Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

2 Jul 2019

The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.

Read more 
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

1 Jul 2019

Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

Read more